Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines various methods for assessing hair growth in women, highlighting the usefulness of the mFG visual scoring method for diagnosing hirsutism despite its limitations.

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

This study determined that an mFG score of 5 or greater defines hirsutism among Southern Chinese women, with prevalence and score thresholds decreasing with age.

This review discusses hirsutism in women with PCOS who present with normal androgen levels and highlights diagnostic challenges, reporting no new clinical findings.

This review discusses the various causes of hirsutism other than PCOS, emphasizing the importance of distinguishing potentially life-threatening conditions like androgen-secreting tumors from more benign causes; it reports no new clinical findings.

The document concludes that treatments for female hair loss and excessive hair growth are temporary and not well-studied.

This case report identified ovarian hyperthecosis as the cause of recent-onset androgenic symptoms in a 73-year-old woman, which was confirmed by ovary removal and led to symptom improvement.

This review discusses the relationship between acne, body hair, and androgenic stimulation in adolescent girls, emphasizing treatment decisions based on disease severity rather than endocrine findings.

This review examines the causes, assessment, and treatment options for hirsutism but presents no new clinical findings, highlighting the need for further research on managing this condition.

This article explores evidence for a rational strategy in the endocrine and metabolic management of patients with excess body hair or scalp loss and reports no new clinical results.

This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.

This article reviews the diagnosis and management of hirsutism in women, discussing its causes, assessment, and treatment options; no new clinical findings are included.

This review examines the causes, assessment, and treatments of hirsutism and highlights the need for future research in managing this condition but presents no new research findings.

Excessive hair growth in women can be treated with medications like spironolactone and finasteride, and male-pattern baldness in women can be improved with similar treatments.

Spironolactone helps reduce hair growth in women with hirsutism but may cause menstrual irregularities.

This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This article discusses evaluation and treatment options for a 19-year-old woman with slowly progressive hair growth and reports no new clinical findings.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

This review discusses the diagnosis and treatment of hirsutism, emphasizing that a systematic evaluation can determine its cause, while combination therapy effectively manages the condition for most patients.

This study suggests that metformin may be more effective than Dianette in treating moderate to severe hirsutism in women with PCOS, while also reducing markers of insulin resistance.

This study found that shorter CAG-repeat lengths in the androgen receptor may be associated with the development of androgen-mediated skin disorders like androgenetic alopecia, acne, and hirsutism in both men and women.

This study reported that spironolactone at 200 mg/day significantly improved facial hair growth in women with hirsutism and showed a sustained reduction in ovarian androgens over one year.

This article discusses treatments for hirsutism and acne in women with polycystic ovary syndrome, suggesting that lower doses of current medications maintain efficacy while reducing cost and side effects, but reports no new clinical results.

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.

This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.

In this study of women with hirsutism or androgenic alopecia, diverse underlying endocrine disorders including polycystic ovaries and various enzyme deficiencies were detected, often associated with elevated testosterone levels.

This study found that combining flutamide with an oral contraceptive significantly reduced hirsutism, acne, and seborrhea in patients after seven months, without significant side effects.

This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.